Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05199311 · ClinicalTrials.gov registry record · Phase 1

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Hackensack Meridian Health.

Recruiting
Registry status
Phase 1
Development phase
66
Enrollment target
2
Study locations

NCT05199311 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 66 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05199311, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Hackensack Meridian Health.

RECRUITING
Registry status
Phase 1
Development phase
66 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Iberdomide
  • DRUG Carfilzomib
  • DRUG Oral Dexamethasone

Study Locations (2)

District of Columbia

  • Lombardi Comprehensive Cancer Center - Washington D.C.

New Jersey

  • John Theurer Cancer Center - Hackensack

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2022-05-13
Est. Completion 2026-06
Phase Phase 1

Sponsor

Hackensack Meridian Health

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05199311

The ClinicalTrials.gov registry entry for NCT05199311 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (88% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Iberdomide is the first listed.

NCT05199311 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05199311 about?

NCT05199311 is a clinical study titled "Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma". This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

What is the current status of trial NCT05199311?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2022-05-13. Estimated completion is 2026-06.

What conditions does trial NCT05199311 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05199311?

The interventions under investigation include: Iberdomide (DRUG), Carfilzomib (DRUG), Oral Dexamethasone (DRUG).

Who is sponsoring clinical trial NCT05199311?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05199311 being conducted?

This trial has 2 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.